End Brexit uncertainty for at-risk UK pharma sector, says cross-party committee

The prospect of leaving the European Union (EU) without an agreement that protects the UK’s pharmaceutical industry would be disastrous for just about everyone with a stake in the sector – from drugmakers to patients.

That is the stark conclusion of a report published on Thursday by the Business, Energy and Industrial Strategy (BEIS) Committee in its latest analysis on the effect the UK’s withdrawal from the EU will have on a sector of the economy.

"The government’s own analysis identifies pharmaceuticals as the sector for which UK/EU market access is the most important given the industry is reliant on friction-free border movement for their products"